Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MOD-6031 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Cohort 1 | EXPERIMENTAL | 20mg MOD-6031 / Placebo |
| Dose Cohort 2 | EXPERIMENTAL | 50mg MOD-6031 / Placebo |
| Dose Cohort 3 | EXPERIMENTAL | 100mg MOD-6031 / Placebo |
| Dose Cohort 4 | EXPERIMENTAL | 150mg MOD-6031 / Placebo |
| Dose Cohort 5 | EXPERIMENTAL | 200mg MOD-6031 / Placebo |
| Name | Type | Description |
|---|---|---|
| MOD-6031 | DRUG | - |
| Placebo control | OTHER | - |
Inclusion Criteria: * Healthy male, between 18 to 55 years of age. * BMI 27-35 Kg/m2 (inclusive). * Generally good health. * Triglyceride ≤ 400mg/ml * ECG with no clinically significant abnormalities. * Negative HIV, hepatitis B or hepatitis C serology tests at screening * No significant abnormalit...
Top 20 of 32 competitors
MOD-6031 is an investigational small molecule being developed for the treatment of obesity. It is in Phase 1 clinical development and has been studied in healthy overweight or obese subjects. The drug is being developed by Opko Health Inc. and is intended to address metabolic conditions related to obesity.
MOD-6031 is a small molecule being developed for obesity, but its specific molecular target has not been disclosed. The drug is in Phase 1 clinical development and has been evaluated in a single-dose, dose-escalation study in healthy overweight or obese subjects. Further details about its mechanism of action are not available.
MOD-6031 is being developed by Opko Health Inc., a biopharmaceutical company listed on the stock exchange under the ticker OPK. The drug is an investigational small molecule for the treatment of obesity and is currently in Phase 1 clinical development.
MOD-6031 is in Phase 1 clinical development. It has completed one Phase 1 trial, a single-dose, dose-escalation study in healthy overweight or obese subjects. The drug is investigational and has not been approved by regulatory authorities. It is being developed for the treatment of obesity.
MOD-6031 has one completed clinical trial, NCT02692781, titled "A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects." This Phase 1 study enrolled 32 male participants in Israel and was a controlled, randomized trial. The drug is being developed for obesity.